Faes Farma, S.A.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Faes Farma, S.A.
As the COVID-19 pandemic wore on, industry clamored for the US FDA to re-inspect troubled drug manufacturing plants remotely if need be to clear them for new approvals. Now FDA investigators are out in force and early returns from Sun, Aurobindo, Lupin and Sterling suggest these re-inspections will be as tough as ever.
The partners released positive data from a Phase III study of their resistant hypertension drug candidate, aprocitentan, and have already started talks with regulators, but its commercial prospects remain uncertain.
Private Company Edition: 5AM revealed two funds totaling $450m and $300m, V-Bio raised a €110m venture capital fund and AXA IM Alts committed $500m for health care private equity deals. Also, TRIANA launched with $110m and the AMR Action Fund backs Adaptive Phage Therapeutics.
Pharma in India draws on celebrity endorsement to spotlight specific disease conditions, with social media adding new dimensions to these efforts. But do these campaigns, now facing increasing disclosure scrutiny more widely, deliver a return on investment?
- Generic Drugs
- OTC, Consumer